Canaccord lowered the firm’s price target on Health Catalyst to $11 from $14 and keeps a Buy rating on the shares. The firm said they were encouraged with management’s commentary on shifting tone of prospective client conversations to potentially catalyze revenue growth in higher margin offerings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst sees FY23 revenue $291M-$296M, consensus $293.78M
- Health Catalyst sees Q4 revenue $70.1M-$75.1M, consensus $73.96M
- Health Catalyst reports Q3 EPS (39c), may not compare to consensus (2c)
- Health Catalyst announces multi-year contract with Accountable Health Partners
- Health Catalyst Reports Third Quarter 2023 Results
